Products for Research Use Only
RegisterLogin

SRX3177

CAT: 0804-HY-153894-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153894-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer[1][2].
CAS Number
2241237-51-2
UNSPSC
12352005
Target
CDK; Epigenetic Reader Domain; NF-κB; PI3K; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Epigenetics; NF-κB; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection; Inflammation/Immunology; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/srx3177.html
Purity
99.59
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC=C(NC5=NC6=C(C=C(N6C7CCCC7)C(N(C)C)=O)C=N5)C=C4
Molecular Formula
C31H32N6O4S
Molecular Weight
584.69
References & Citations
[1]Burgoyne AM, et al. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020 Jul 28;6 (1) :49.|[2]Pandey K, et al. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2. Antiviral Res. 2024 Jul;227:105904.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; CDK4; CDK6; PI3Kα; PI3Kβ; PI3Kγ

Related Products

CatalogName
HY-136198-01SRX3207

Alternative Products

CatalogName
C03292-01SRX3177
A24272-100SRX3177 100mg
A24272-50SRX3177 50mg
A24272-5SRX3177 5mg
A24272-10SRX3177 10mg

Popular Products